PT-141 (Bremelanotide) and Metformin Interaction

Why This Combination Comes Up

Bremelanotide (Vyleesi) is an FDA-approved melanocortin-4 receptor (MC4R) agonist indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Metformin remains the first-line pharmacotherapy for type 2 diabetes mellitus (T2DM), prescribed to over 90 million patients in the United States alone according to IQVIA prescription data [2]. The overlap is predictable. Women with T2DM experience HSDD at roughly twice the rate of age-matched controls, a finding reported in a 2016 cross-sectional analysis (N=613) published in the Journal of Sexual Medicine [3]. Clinicians managing both conditions will encounter this drug pair regularly, and patients searching for interaction data deserve a clear, evidence-based answer.

The short version: these two drugs operate through entirely separate metabolic and receptor pathways. No pharmacokinetic conflict exists. The conversation worth having centers on pharmacodynamic overlap, specifically nausea burden and transient hemodynamic shifts, and how to manage those in practice.

Pharmacokinetic Analysis: No Metabolic Collision

Bremelanotide and metformin share almost nothing in their absorption, distribution, metabolism, or excretion profiles. That separation is what makes this combination low-risk from a PK standpoint.

Bremelanotide is a cyclic heptapeptide administered subcutaneously. It reaches peak plasma concentration (Tmax) approximately 1 hour post-injection, with an absolute bioavailability of roughly 100% via the SC route [1]. According to the Vyleesi prescribing information, bremelanotide undergoes hydrolysis into metabolic fragments rather than CYP-mediated oxidation. It is not a substrate, inhibitor, or inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 [1]. The drug also showed no clinically meaningful inhibition of P-glycoprotein (P-gp), OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2-K in in-vitro transporter assays [1].

Metformin, by contrast, is not metabolized at all. It is absorbed from the GI tract, circulates unbound to plasma proteins, and is excreted unchanged in the urine via active tubular secretion through OCT2 and MATE1/MATE2-K transporters [2]. Its elimination half-life is approximately 6.2 hours in plasma. Because bremelanotide does not inhibit OCT2, MATE1, or MATE2-K, it cannot alter metformin's renal clearance [1][2].

The FDA label for bremelanotide does flag one PK interaction of note. Co-administration with naltrexone decreased bremelanotide exposure (AUC) by approximately 24%, though this involves naltrexone's effects on peptide absorption, not a shared pathway with metformin [1]. No equivalent signal exists for biguanides.

Pharmacodynamic Considerations: Where Clinical Attention Belongs

The absence of a PK interaction does not mean clinicians can ignore this combination entirely. Two pharmacodynamic areas require monitoring.

Blood pressure. Bremelanotide activates central melanocortin receptors, which triggers a transient rise in blood pressure. In the RECONNECT phase 3 trials (N=1,247), bremelanotide 1.75 mg SC produced a mean systolic BP increase of 6 mmHg and a mean diastolic increase of 3 mmHg, with a simultaneous decrease in heart rate of 5 bpm [4]. These effects peaked at 2 to 4 hours post-dose and resolved within 12 hours. The FDA label contraindicates bremelanotide in patients with uncontrolled hypertension or known cardiovascular disease for this reason [1].

Metformin itself does not raise blood pressure. Some data suggest a modest BP-lowering effect over time in insulin-resistant populations [5]. The concern is not synergistic hypertension but rather the additive risk in a patient whose baseline BP is already borderline. A woman with T2DM, obesity, and resting systolic pressure of 138 mmHg might tolerate metformin without issue yet cross into a clinically significant hypertensive range during the 2-to-4-hour window after a bremelanotide injection.

Nausea and GI effects. This is the overlap patients will feel most. In the RECONNECT trials, 40% of women receiving bremelanotide reported nausea, compared to 1% in the placebo arm [4]. The nausea was dose-dependent, typically mild to moderate, and self-limited within hours. Metformin's immediate-release formulation carries a nausea incidence of up to 25.5% and diarrhea in 53.2% of patients in early titration, per its FDA label [2]. Extended-release metformin reduces but does not eliminate these GI complaints.

When both drugs are used on the same day, the aggregate probability of GI distress is not simply additive (the mechanisms differ: central MC4R activation versus local GI irritation and altered bile acid metabolism). But from the patient's perspective, the experience compounds. Timing the bremelanotide dose for the evening, well after the last metformin dose has been absorbed, can reduce the window of overlapping nausea.

Severity Rating and DDI Database Classification

Major drug interaction databases (Lexicomp, Clinical Pharmacology, Micromedex) do not list a formal interaction between bremelanotide and metformin as of early 2026. This is consistent with the pharmacokinetic data: no shared metabolic enzymes, no shared transporters, no competitive protein binding.

The Vyleesi prescribing information identifies only two named drug interactions. The first is with naltrexone (decreased bremelanotide AUC). The second is a class-level caution for drugs that slow intestinal motility (bremelanotide transiently reduces gastric emptying), which could theoretically delay absorption of orally administered medications [1]. Metformin's absorption window is in the small intestine, and a modest slowing of gastric transit has not been shown to alter metformin's overall bioavailability in a clinically meaningful way.

"Based on the in vitro evaluation, bremelanotide is not expected to cause drug interactions via major drug metabolizing enzymes or transporters at clinically relevant concentrations," states the FDA-approved Vyleesi label [1]. That language is unusually definitive for a prescribing information document and reflects the clean transporter and CYP profile from phase 1 studies.

Monitoring Parameters for Concurrent Use

Even without a formal interaction, the following monitoring protocol is reasonable for patients using both agents.

Before initiating bremelanotide: Confirm baseline blood pressure is below 140/90 mmHg on the patient's current metformin regimen. The Vyleesi label recommends a cardiovascular assessment before prescribing [1]. For patients with T2DM, this overlaps with standard care. Check the most recent eGFR, since metformin dosing depends on renal function (contraindicated at eGFR <30 mL/min, dose reduction at eGFR 30 to 45 mL/min per ADA guidelines) and bremelanotide's renal excretion fraction, while not predominant, means severe renal impairment could prolong exposure [2][6].

At each use: Patients should be counseled to check blood pressure before and 1 hour after their first several bremelanotide injections. Home BP monitoring is sufficient. If systolic pressure exceeds 160 mmHg or diastolic exceeds 100 mmHg post-injection, the patient should contact their prescriber before using additional doses.

Ongoing: The Endocrine Society's 2022 clinical practice guideline on female sexual dysfunction recommends periodic reassessment of sexual function using validated tools such as the FSFI (Female Sexual Function Index) [7]. For patients on metformin, HbA1c monitoring every 3 to 6 months serves double duty: glycemic control directly influences sexual function in women with T2DM, and improved glucose management may reduce the need for bremelanotide over time.

Dose Adjustment: None Required, With Caveats

No dose adjustment is necessary for either drug when used together. Bremelanotide is dosed at 1.75 mg SC as needed, with a maximum of 1 injection per 24 hours and no more than 8 injections per month [1]. Metformin dosing follows standard titration schedules (typically 500 mg once or twice daily, titrated to a maximum of 2,000 to 2 to 550 mg daily in divided doses) [2].

The caveat applies to patients with moderate renal impairment (eGFR 30 to 60 mL/min). In this group, metformin should already be dose-reduced per FDA guidance, and bremelanotide's elimination may be modestly prolonged. No formal renal impairment PK study for bremelanotide has been published. The Vyleesi label notes that 44% to 64% of the administered dose is recovered in urine, primarily as metabolic fragments [1]. Clinicians should exercise standard caution and may consider longer intervals between bremelanotide doses in patients with eGFR <45 mL/min, though no specific guideline mandates this.

Patient Counseling Points

Five practical points for patients receiving both medications:

Timing separation reduces nausea. Take metformin with the morning and evening meals as usual. If using bremelanotide, inject it at least 45 minutes before anticipated sexual activity, ideally in the evening and at least 2 hours after the last metformin dose. This staggers the peak nausea windows.

Eat before injecting. The Vyleesi prescribing information notes that an antiemetic can be considered with the first dose [1]. A light meal 30 to 60 minutes before injection also blunts nausea. Since metformin should be taken with food to reduce GI distress, the evening meal can serve both purposes.

Watch for flushing, not just nausea. Bremelanotide causes facial flushing in approximately 20% of users and transient skin hyperpigmentation in 1% [4]. These are benign but can alarm patients if they are not warned in advance. Neither effect interacts with metformin.

Do not exceed dosing limits. The 8-dose monthly cap on bremelanotide exists because of cumulative effects on melanin deposition and blood pressure. Patients should track doses with a calendar or app. "Patients should not use more than one dose within 24 hours or more than 8 doses per month," per the Vyleesi medication guide [1].

Report persistent GI symptoms. If nausea or vomiting persists beyond 4 hours after a bremelanotide injection or worsens on days when both drugs are taken, clinicians should re-evaluate. Severe, sustained vomiting in a metformin-treated patient raises theoretical risk of dehydration-related lactic acidosis, though this remains a rare event. The FDA's 2024 metformin safety communication reinforced that lactic acidosis is uncommon (estimated at 3 to 10 cases per 100,000 patient-years) but carries high mortality when it occurs [8].

Special Populations

Women with polycystic ovary syndrome (PCOS). PCOS is the most common endocrine disorder in reproductive-age women, affecting 6% to 12% of this population per CDC estimates [9]. Metformin is frequently prescribed off-label for PCOS-related insulin resistance, and sexual dysfunction is reported in up to 60% of women with PCOS according to a 2020 meta-analysis (N=3,032) [10]. This population represents a high-probability overlap for bremelanotide and metformin co-prescription. The same monitoring principles apply, with added attention to androgen levels, since bremelanotide's efficacy may vary with hormonal milieu.

Women on concurrent GLP-1 receptor agonists. Patients using metformin often also receive semaglutide, tirzepatide, or other GLP-1 RAs. GLP-1 RAs independently slow gastric emptying and carry high nausea rates (STEP-1 [N=1,961] reported nausea in 44.2% of participants on semaglutide 2.4 mg) [11]. Adding bremelanotide to a GLP-1/metformin regimen creates a triple-nausea scenario. Clinicians should consider whether the patient has stabilized on the GLP-1 RA (nausea typically attenuates by weeks 8 to 12 of titration) before introducing bremelanotide.

Patients with hepatic impairment. Bremelanotide showed no clinically significant PK changes in mild or moderate hepatic impairment (Child-Pugh A and B) [1]. Metformin is not hepatically metabolized. No dose adjustment is needed for either drug in mild to moderate liver disease.

The Bottom Line on Concurrent Use

The bremelanotide-metformin combination has no pharmacokinetic interaction, no shared metabolic pathway, and no formal contraindication. The clinical management task is pharmacodynamic: controlling GI symptoms through dose timing and monitoring blood pressure during the 2-to-4-hour post-injection window. For the estimated 9.4% of premenopausal women with T2DM who meet criteria for HSDD [3], this combination fills a genuine unmet need without requiring dose modifications to either agent. Baseline blood pressure should be below 140/90 mmHg, eGFR should be confirmed above 30 mL/min, and patients should separate doses by at least 2 hours to minimize overlapping nausea.